6lpk: Difference between revisions
No edit summary |
No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==A2AR crystallized in EROCOC17+4, LCP-SFX at 293 K== | |||
<StructureSection load='6lpk' size='340' side='right'caption='[[6lpk]], [[Resolution|resolution]] 1.80Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LPK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6LPK FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.8Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=8K6:OCTADECANE'>8K6</scene>, <scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=D10:DECANE'>D10</scene>, <scene name='pdbligand=D12:DODECANE'>D12</scene>, <scene name='pdbligand=ER0:[(2~{R},3~{S})-2,3,4-tris(oxidanyl)butyl]+(5~{R},9~{R},13~{R})-5,9,13,17-tetramethyloctadecanoate'>ER0</scene>, <scene name='pdbligand=HEX:HEXANE'>HEX</scene>, <scene name='pdbligand=MYS:PENTADECANE'>MYS</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=OCT:N-OCTANE'>OCT</scene>, <scene name='pdbligand=TRD:TRIDECANE'>TRD</scene>, <scene name='pdbligand=UND:UNDECANE'>UND</scene>, <scene name='pdbligand=ZMA:4-{2-[(7-AMINO-2-FURAN-2-YL[1,2,4]TRIAZOLO[1,5-A][1,3,5]TRIAZIN-5-YL)AMINO]ETHYL}PHENOL'>ZMA</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6lpk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6lpk OCA], [https://pdbe.org/6lpk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6lpk RCSB], [https://www.ebi.ac.uk/pdbsum/6lpk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6lpk ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
In meso crystallization of membrane proteins relies on the use of lipids capable of forming a lipidic cubic phase (LCP). However, almost all previous crystallization trials have used monoacylglycerols, with 1-(cis-9-octadecanoyl)-rac-glycerol (MO) being the most widely used lipid. We now report that EROCOC17+4 mixed with 10% (w/w) cholesterol (Fig. 1) serves as a new matrix for crystallization and a crystal delivery medium in the serial femtosecond crystallography of Adenosine A2A receptor (A2AR). The structures of EROCOC17+4-matrix grown A2AR crystals were determined at 2.0 A resolution by serial synchrotron rotation crystallography at a cryogenic temperature, and at 1.8 A by LCP-serial femtosecond crystallography, using an X-ray free-electron laser at 4 and 20 degrees C sample temperatures, and are comparable to the structure of the MO-matrix grown A2AR crystal (PDB ID: 4EIY). Moreover, X-ray scattering measurements indicated that the EROCOC17+4/water system did not form the crystalline LC phase at least down to - 20 degrees C, in marked contrast to the equilibrium MO/water system, which transforms into the crystalline LC phase below about 17 degrees C. As the LC phase formation within the LCP-matrix causes difficulties in protein crystallography experiments in meso, this feature of EROCOC17+4 will expand the utility of the in meso method. | |||
Isoprenoid-chained lipid EROCOC17+4: a new matrix for membrane protein crystallization and a crystal delivery medium in serial femtosecond crystallography.,Ihara K, Hato M, Nakane T, Yamashita K, Kimura-Someya T, Hosaka T, Ishizuka-Katsura Y, Tanaka R, Tanaka T, Sugahara M, Hirata K, Yamamoto M, Nureki O, Tono K, Nango E, Iwata S, Shirouzu M Sci Rep. 2020 Nov 9;10(1):19305. doi: 10.1038/s41598-020-76277-x. PMID:33168855<ref>PMID:33168855</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 6lpk" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Adenosine A2A receptor 3D structures|Adenosine A2A receptor 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Hato M]] | |||
[[Category: Hirata K]] | |||
[[Category: Hosaka T]] | |||
[[Category: Ihara K]] | |||
[[Category: Ishizuka-Katsura Y]] | |||
[[Category: Iwata S]] | |||
[[Category: Kimura-Someya T]] | |||
[[Category: Nakane T]] | |||
[[Category: Nango E]] | |||
[[Category: Nureki O]] | |||
[[Category: Shirouzu M]] | |||
[[Category: Sugahara M]] | |||
[[Category: Tanaka R]] | |||
[[Category: Tanaka T]] | |||
[[Category: Tono K]] | |||
[[Category: Yamamoto M]] | |||
[[Category: Yamashita K]] |